Emergent BioSolutions Inc. Company Profile
NYSE: EBSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Emergent BioSolutions at a glance
Emergent BioSolutions Inc. (NYSE: EBS) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Gaithersburg, MD. Emergent BioSolutions is led by Mr. Joseph C. Papa Jr., M.B.A., R.Ph. and employs about 900 people. The company's shares have traded publicly since 2006.
At a market capitalization of $259.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001367644, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Emergent BioSolutions do?
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intravenous (ANTHRASIL), a polyclonal antibody therapeutic for the treatment of inhalational anthrax; Botulism Antitoxin Heptavalent (BAT), an equine plasma antitoxin for the treatment of symptomatic botulism; BioThrax, an anthrax vaccine; CYFENDUS, a vaccine for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; Ebanga, a monoclonal antibody for the treatment of infection caused by Orthoebolavirus zairense; Raxibacumab injection, a monoclonal antibody therapeutic for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis; TEMBEXA, an oral antiviral for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; and CNJ-016, a polyclonal antibody therapeutic to address complications from smallpox vaccination. It also provides NARCAN and KLOXXADO nasal sprays for the emergency treatment of known or suspected opioid overdose. In addition, the company offers contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, analytical development, and suite reservation services. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Business description based on the company's public filings.
Company information
- Legal name
- Emergent BioSolutions Inc.
- Ticker
- NYSE: EBS
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joseph C. Papa Jr., M.B.A., R.Ph.
- Employees
- 900
- Headquarters
- 300 Professional Drive, Gaithersburg, MD, United States
- Phone
- 240 631 3200
- Website
- emergentbiosolutions.com
- IPO year
- 2006
- Market cap
- $259.65M
- SEC CIK
- 0001367644
- Latest annual report
- 10-K · Feb 27, 2026
Companies similar to Emergent BioSolutions
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALTAltimmune Inc. | 1.33 | -5.67% | $258.80M | vs EBS |
| PRLDPrelude Therapeutics Incorporated | 3.23 | -0.77% | $258.63M | vs EBS |
| VCREVicore Pharma Holding AB ADR | 9.41 | -5.09% | $264.89M | vs EBS |
| QTTBQ32 Bio Inc. | 8.34 | -1.65% | $249.57M | vs EBS |
| GALTGalectin Therapeutics Inc. | 2.69 | -4.27% | $271.35M | vs EBS |
| TTRXTurn Therapeutics Inc. | 8.10 | -6.31% | $247.49M | vs EBS |
| LFCRLifecore Biomedical Inc. | 6.39 | +0.31% | $242.22M | vs EBS |
| RLMDRelmada Therapeutics Inc. | 2.62 | -15.76% | $279.54M | vs EBS |